Kawamori Ryuzo, Valensi Paul
a Department of Medicine, Metabolism & Endocrinology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
b Department of Endocrinology Diabetology Nutrition, Paris Nord University, AP-HP, Jean Verdier Hospital, CRNH-IdF, Bondy, France.
Expert Rev Endocrinol Metab. 2010 Jul;5(4):507-516. doi: 10.1586/eem.10.31.
The IMPROVE™ study is the largest observational study of therapy in Type 2 diabetes mellitus to date. It is a multinational study investigating the safety and efficacy of biphasic insulin aspart 30/70 (BIAsp 30) in the routine management of patients with Type 2 diabetes mellitus. Five published reports on this study have provided baseline demographic information for patients receiving BIAsp 30 in eight countries, information on the safety and efficacy outcomes for those patients and analyses of three subgroups of patients who were insulin-naive, receiving basal insulin or receiving biphasic human insulin before the start of the study. These subanalyses provided information on the optimal prescribing and dosing strategies when starting treatment with BIAsp 30 in these groups of patients in normal clinical practice. The study extends the results from clinical trials of BIAsp 30 and confirms its benefits in routine care, in a large, global, heterogeneous patient population.
IMPROVE™研究是迄今为止针对2型糖尿病治疗的最大规模观察性研究。这是一项多国研究，旨在调查双相门冬胰岛素30/70（BIAsp 30）在2型糖尿病患者常规管理中的安全性和有效性。关于这项研究的五篇已发表报告提供了八个国家接受BIAsp 30治疗患者的基线人口统计学信息、这些患者的安全性和有效性结果信息，以及对研究开始前未使用过胰岛素、正在接受基础胰岛素治疗或正在接受双相人胰岛素治疗的三组亚组患者的分析。这些亚组分析提供了在正常临床实践中，对这些患者群体开始使用BIAsp 30治疗时的最佳处方和给药策略信息。该研究扩展了BIAsp 30临床试验的结果，并在一个大型、全球、异质性患者群体中证实了其在常规护理中的益处。
